Under AFP Surveillance, follow-up examination is done after (For residual paralysis)
**Question:** Under AFP Surveillance, follow-up examination is done after (For residual paralysis)
**Core Concept:** AFP surveillance refers to monitoring serum alpha-fetoprotein (AFP) levels in patients who have undergone treatment for neonatal hypotonia or paralysis caused by congenital hypothyroidism, particularly in cases where thyroid hormone replacement therapy is initiated during the neonatal period. AFP is a marker for abnormal cell growth, and its elevated levels indicate the potential persistence or recurrence of the disease.
**Why the Correct Answer is Right:**
Correct Answer: C. 4-6 weeks
In the context of AFP surveillance, follow-up examinations are crucial for evaluating the effectiveness of treatment and detecting any residual paralysis or recurrence of congenital hypothyroidism. The correct timing for follow-up examination after initiating therapy is crucial to ensure accurate results.
**Why Each Wrong Option is Incorrect:**
A. 1 month: An insufficient time period to assess the treatment response and detect any residual paralysis or elevated AFP levels.
B. 6 months: Although this is a reasonable time frame for assessing the long-term effects of treatment, it does not specifically address the need for early detection of residual paralysis or elevated AFP levels.
D. Years: This is too long a period for early detection of residual paralysis or recurrence of congenital hypothyroidism.
**Why the Correct Answer is Right (C):**
The optimal time for follow-up examination after initiating thyroid hormone replacement therapy for neonatal hypothyroidism is 4-6 weeks. This time frame allows for the early detection of residual paralysis and elevation of AFP levels due to the persistence or recurrence of congenital hypothyroidism. Timely detection enables appropriate intervention and improves the prognosis of the patient.
**Why Each Wrong Option is Incorrect (A, B, and D):**
A. 1 month: Insufficient time for evaluating the treatment response and detecting any residual paralysis or elevated AFP levels.
B. 6 months: Relevant for long-term assessment but does not address the need for early detection of residual paralysis or elevated AFP levels.
D. Years: This time frame is too long for early detection of residual paralysis or recurrence of congenital hypothyroidism.
**Clinical Pearl:** Timely follow-up examinations, such as 4-6 weeks after initiating therapy, are essential for assessing the effectiveness of treatment, detecting residual paralysis, and monitoring AFP levels in neonates with hypothyroidism. This ensures prompt intervention and improves patient prognosis.